Hematological Improvement of Patients with Active Rheumatoid Arthritis by β-D-Mannuronic Acid (M2000) as a Novel NSAID with Immunosuppressive Property


خلاصه: Copyright© Autumn 2017, Iran J Allergy Asthma Immunol. All rights reserved. 433 Published by Tehran University of Medical Sciences (http://ijaai.tums.ac.ir) ORIGINAL ARTICLE Iran J Allergy Asthma Immunol October 2017; 16(5): 433-442. Hematological Improvement of Patients with Active Rheumatoid Arthritis by β-D-Mannuronic Acid (M2000) as a Novel NSAID with Immunosuppressive Property Hossein Ahmadi1, Ahmad Reza Jamshidi2, Mahdi Mahmoudi2, Farhad Gharibdoost2, Mahdi Vojdanian2, Mohammad Javad Fattahi1,3, Noushin Rastkari4, Zahra Aghazadeh1, and Abbas Mirshafiey1 1 Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran 2 Rheumatology Research Centre, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran 3 Institute for Cancer Research (ICR), School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran 4 Center for Air Pollution Research (CAPR), Institute for Environmental Research (IER), Tehran University of Medical Sciences, Tehran, Iran Received: 23 January 2017; Received in revReceived: 23 January 2017; Received in revReceived: 23 January 2017; Received in revReceived: 23 January 2017; Received in revReceived: 23 January 2017; Received in revReceived: 23 January 2017; Received in revReceived: 23 January 2017; Received in revReceived: 23 January 2017; Received in revReceived: 23 January 2017; Received in revReceived: 23 January 2017; Received in revReceived: 23 January 2017; Received in revReceived: 23 January 2017; Received in revReceived: 23 January 2017; Received in revReceived: 23 January 2017; Received in rev Received: 23 January 2017; Received in revReceived: 23 January 2017; Received in revReceived: 23 January 2017; Received in revReceived: 23 January 2017; Received in rev Received: 23 January 2017; Received in revReceived: 23 January 2017; Received in revReceived: 23 January 2017; Received in revReceived: 23 January 2017; Received in revReceived: 23 January 2017; Received in revReceived: 23 January 2017; Received in revReceived: 23 January 2017; Received in revReceived: 23 January 2017; Received in revReceived: 23 January 2017; Received in revReceived: 23 January 2017; Received in revReceived: 23 January 2017; Received in revReceived: 23 January 2017; Received in revReceived: 23 January 2017; Received in revReceived: 23 January 2017; Received in revReceived: 23 January 2017; Received in revReceived: 23 January 2017; Received in revReceived: 23 January 2017; Received in revReceived: 23 January 2017; Received in revReceived: 23 January 2017; Received in revReceived: 23 January 2017; Received in rev ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017 ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017 ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017 ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017 ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017 ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017ised form: 12 February 2017; Accepted: March 2017 ABSTRACT The aim of this study was to investigate the effect of β-D-mannuronic acid (M2000) on hematological parameters in patients with active rheumatoid arthritis. This study was conducted on 25 patients with active rheumatoid arthritis (RA) (identifier: IRCT2014011213739N2). M2000 was administered orally for anemic and non-anemic RA patients at a dose of 500 mg twice daily for 12 weeks. The patients were permitted to continue the conventional treatments excluding NSAIDs. Blood samples were collected at baseline, 4 and 12 weeks after drug administration and were tested for hematological parameters. Moreover, serum levels of TNF-α and IL-6 were analysed before and after M2000 therapy compared to healthy controls using enzyme linked immunosorbent assay method.